Margaret Block
Medical Journal Articles
| ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). |
Read Article |
|
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients |
Read Article |
